Dr Lal Pathlabs, a company in the Healthcare Service Provider industry, reported revenue of ₹874 crore and net profit of ₹194 crore for the September 2026 quarter.
Dr Lal Pathlabs (NSE: LALPATHLAB) closed at ₹2,006.00 on 20 Nov 2026, up 28.3% over the past year. Its market capitalisation is ₹33,670 crore and it trades at 55.6 times earnings.
Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.